Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
Phase 2 Completed
75 enrolled 17 charts
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
Phase 1 Completed
Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
Phase 2 Completed
11 enrolled 11 charts
Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
Phase 1 Completed
29 enrolled
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
Phase 2 Completed
30 enrolled 19 charts
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Phase 1 Completed
55 enrolled
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
Phase 1 Completed
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
Phase 1 Completed
31 enrolled
Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma
Phase 2 Completed
90 enrolled
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
Phase 1 Completed
72 enrolled
Cilengitide in Treating Children With Refractory Primary Brain Tumors
Phase 1 Completed
24 enrolled
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
Phase 1 Completed
45 enrolled
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
Phase 1 Completed
55 enrolled
Lobradimil and Carboplatin in Treating Children With Brain Tumors
Phase 2 Completed
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
Phase 2 Completed
30 enrolled
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
Phase 1 Completed
30 enrolled
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
Phase 1 Completed
20 enrolled
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
Phase 2 Completed
180 enrolled
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
Phase 1 Completed
24 enrolled
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
Phase 1 Completed
27 enrolled
O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors
Phase 1 Completed
36 enrolled
Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma
Phase 2 Completed
200 enrolled
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
Phase 1 Completed
30 enrolled
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
Phase 1 Completed
30 enrolled
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
Phase 1 Completed
30 enrolled
ABT-751 in Treating Young Patients With Refractory Solid Tumors
Phase 1 Completed
90 enrolled
Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors
Phase 1 Completed
26 enrolled